---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/43267122.md"
description: "$Creative Medical Tech(CELZ.US) rose +72%, triggered by the implementation of a key patent; $Ensysce Biosciences(ENSC.US) rose +45%, securing FDA recognition while completing the acquisition of its CRPS candidate pipeline. Both are micro-cap biotechs. Events like patents and regulatory recognitions can be amplified into double-digit rallies in small caps, but recognition does not equal approval, and patents do not equal revenue. The real focus should be on the next steps—whether the patent can generate licensing revenue and whether the CRPS pipeline can advance to pivotal clinical trials. Until then, this kind of surge resembles event premium rather than value re-rating."
datetime: "2026-08-07T09:41:23.000Z"
locales:
  - [en](https://longbridge.com/en/topics/43267122.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/43267122.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/43267122.md)
author: "[本职喵星人](https://longbridge.com/en/profiles/27713076.md)"
---

# $Creative Medical Tech(CELZ.US) rose +72%, trigger…


### Related Stocks

- [CELZ.US](https://longbridge.com/en/quote/CELZ.US.md)
- [ENSC.US](https://longbridge.com/en/quote/ENSC.US.md)
- [ENSCW.US](https://longbridge.com/en/quote/ENSCW.US.md)